ONCAlert | 2018 ASCO Annual Meeting
Videos  >  

Dr. David Reardon on Targeting Brain Tumors and Monitoring Resistances

David Reardon, MD
Published Online:3:00 AM, Fri January 29, 2016


David Reardon, MD, clinical director, Center for Neuro-Oncology, Dana-Farber Cancer Institute, discusses identifying certain characteristics in a patient's brain tumor in order to administer better treatment. Reardon says medical professionals should identify the key drivers in a patient's tumor and select the therapy, or combination therapies, that would best target those traits.

Reardon cautions that despite these treatments based on the characteristics of a tumor, medical professionals should be wary of a tumor's ever-changing resistance and ability to adapt. 
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.